share_log

Only Three Days Left To Cash In On China Resources Medical Holdings' (HKG:1515) Dividend

Only Three Days Left To Cash In On China Resources Medical Holdings' (HKG:1515) Dividend

僅剩三天可以兌現華潤醫療控股(HKG: 1515)的股息
Simply Wall St ·  06/02 20:36

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be intrigued to know that China Resources Medical Holdings Company Limited (HKG:1515) is about to go ex-dividend in just three days. The ex-dividend date is one business day before the record date, which is the cut-off date for shareholders to be present on the company's books to be eligible for a dividend payment. The ex-dividend date is important as the process of settlement involves two full business days. So if you miss that date, you would not show up on the company's books on the record date. Accordingly, China Resources Medical Holdings investors that purchase the stock on or after the 7th of June will not receive the dividend, which will be paid on the 19th of July.

一些投資者依靠分紅來增加財富,如果您是那些追求分紅的人之一,您可能會有興趣知道,中國資源醫藥控股有限公司(HKG:1515)即將在三天內派發分紅。除淨日是股東被記錄在公司賬簿上以享有分紅資格的截止日期前的一個工作日。如果錯過了這個日期,您在除淨日後購買的中國資源醫藥控股股票將不會獲得分紅,而分紅將在7月19日支付。

The company's next dividend payment will be CN¥0.06 per share, and in the last 12 months, the company paid a total of CN¥0.06 per share. Based on the last year's worth of payments, China Resources Medical Holdings stock has a trailing yield of around 1.7% on the current share price of HK$3.82. If you buy this business for its dividend, you should have an idea of whether China Resources Medical Holdings's dividend is reliable and sustainable. So we need to check whether the dividend payments are covered, and if earnings are growing.

該公司的下一個分紅爲人民幣0.06元/股,在過去12個月中,該公司每股派發了總額爲人民幣0.06元的分紅。根據過去一年的分紅記錄,中國資源醫藥控股股票在當前股價爲HK$3.82時的跟蹤收益率約爲1.7%。如果您購買該企業是爲了獲得分紅,那麼您應該知道中國資源醫藥控股的分紅是否可靠和持續。因此,我們需要檢查分紅支付是否得到覆蓋,以及收益是否增長。

Dividends are usually paid out of company profits, so if a company pays out more than it earned then its dividend is usually at greater risk of being cut. China Resources Medical Holdings paid out a comfortable 29% of its profit last year. Yet cash flows are even more important than profits for assessing a dividend, so we need to see if the company generated enough cash to pay its distribution. What's good is that dividends were well covered by free cash flow, with the company paying out 6.0% of its cash flow last year.

分紅通常來自公司利潤,因此,如果公司支付的分紅超過其賺取的利潤,那麼其分紅的風險通常更大。中國資源醫藥控股去年支付了舒適的29%的利潤。現金流比利潤對於評估分紅至關重要,因此我們需要看到公司是否產生足夠的現金來支付其派發。令人滿意的是,分紅由自由現金流很好地覆蓋,公司在去年支付了其現金流的6.0%。

It's encouraging to see that the dividend is covered by both profit and cash flow. This generally suggests the dividend is sustainable, as long as earnings don't drop precipitously.

看到股息既有盈利也有現金流的覆蓋是令人鼓舞的。這通常表明股息是可持續的,只要收益沒有急劇下降。

Click here to see the company's payout ratio, plus analyst estimates of its future dividends.

點擊此處查看公司的支付比率以及未來分紅的分析師預期。

historic-dividend
SEHK:1515 Historic Dividend June 3rd 2024
SEHK: 1515歷史分紅2024年6月3日

Have Earnings And Dividends Been Growing?

收益和股息一直在增長嗎?

Businesses with shrinking earnings are tricky from a dividend perspective. Investors love dividends, so if earnings fall and the dividend is reduced, expect a stock to be sold off heavily at the same time. Readers will understand then, why we're concerned to see China Resources Medical Holdings's earnings per share have dropped 10% a year over the past five years. Such a sharp decline casts doubt on the future sustainability of the dividend.

從股息的角度來看,收益萎縮的企業往往頗具挑戰性。投資者喜愛分紅,因此,如果收益下降並且分紅下降,我們預計股票也會同時大幅拋售。讀者將理解我們爲什麼擔心中國資源醫藥控股過去5年每年的每股收益下降了10%。這樣一個急劇下降的趨勢會對未來的分紅可持續性產生影響。

The main way most investors will assess a company's dividend prospects is by checking the historical rate of dividend growth. In the past 10 years, China Resources Medical Holdings has increased its dividend at approximately 1.3% a year on average.

大多數投資者評估公司的分紅前景的主要方式是檢查歷史分紅增長率。在過去的10年中,中國資源醫藥控股每年平均增加約1.3%的股息。

The Bottom Line

還有一件事需要注意的是,我們已經確定了上海醫藥的2個警告信號,了解這些信號應該成爲你的投資過程的一部分。

Has China Resources Medical Holdings got what it takes to maintain its dividend payments? Earnings per share are down meaningfully, although at least the company is paying out a low and conservative percentage of both its earnings and cash flow. It's definitely not great to see earnings falling, but at least there may be some buffer before the dividend needs to be cut. Overall, it's not a bad combination, but we feel that there are likely more attractive dividend prospects out there.

中國資源醫藥控股有能力維持其分紅支付嗎?儘管每股收益下降了,但至少該公司支付的利潤佔盈利和現金流的比例都很低和保守。雖然看到收益下降肯定不太好,但至少在需要削減股息之前,可能會有一些緩衝。總的來說,這不是一個壞組合,但我們認爲可能還有更具吸引力的分紅前景。

In light of that, while China Resources Medical Holdings has an appealing dividend, it's worth knowing the risks involved with this stock. To help with this, we've discovered 2 warning signs for China Resources Medical Holdings that you should be aware of before investing in their shares.

因此,儘管中國資源醫藥控股具有吸引人的分紅,但了解股票的風險非常重要。爲了幫助您,我們發現了2個有關中國資源醫藥控股的警告信號,您應在投資該公司的股票之前了解這些信號。

If you're in the market for strong dividend payers, we recommend checking our selection of top dividend stocks.

如果你在尋找強勁的股息支付者,我們建議查看我們的頂級股息股票選擇。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或者,發送電子郵件至editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論